Fig. 6: BMS309403 reduced the release of profibrotic cytokines by inhibiting TGF-β/Smad3 pathway and restored impaired FAO pathway in fibrotic kidney. | Cell Death & Disease

Fig. 6: BMS309403 reduced the release of profibrotic cytokines by inhibiting TGF-β/Smad3 pathway and restored impaired FAO pathway in fibrotic kidney.

From: Pre-emptive pharmacological inhibition of fatty acid–binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism

Fig. 6

a TGF-β, p-Smad2, and p-Smad3 expression was verified in kidney samples by Western blot. Blots were stripped and reprobed for GAPDH. b RT-qPCR for TGF-β, CTGF, PDGFB, and FGF2 transcripts normalized to Gapdh in kidney tissue. c The changes in PGC1α and PPARγ expression levels were confirmed in mouse kidneys by immunoblotting studies. d Ppargc1a, Pparg, Cpt1a, Cpt2, Acox1, and Acox2 mRNA expression were analyzed by RT-qPCR in total RNA extracts of kidneys from saline- or BMS309403-treated normal and UUO mice. The transcript normalized to Gapdh. Representative images from three independent experiments are shown above. *P < 0.05, **P < 0.01, ***P < 0.001, ns means no statistical significance.

Back to article page